Hyperion DeFi Reports Third Quarter 2025 Financial Results with Record Net Income of $6.6 Million

Management Initiates Q4’25 Adjusted Revenue⁽³⁾ Guidance of 31% to 43% Q-o-Q Growth

Over 13 Million HYPE Tokens Staked to Hyperion’s Validator as of October 31, 2025

Ramping Business Lines Expected to Achieve Positive Operating Cash Flows in 2026

LAGUNA HILLS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid’s native token, HYPE, today reported results for the third quarter ending September 30, 2025.

“This has been an extraordinary six months for Hyperion DeFi, and we are still in the early stages of our evolution,” said Hyunsu Jung, Interim CEO of Hyperion DeFi.

Mr. Jung continued, “We've successfully executed what we believe represents one of the most significant corporate transformations in recent public market history - pivoting from Eyenovia's ophthalmic technology focus to establishing ourselves as a premier institutional gateway to DeFi innovation. In our first full quarter with our new digital asset treasury strategy, not only did we achieve record net income for the Company, but we have established multiple business lines on the Hyperliquid blockchain which we expect to continue to scale through the fourth quarter, into 2026, and beyond.”

Q3'25 Financial Results

• Revenue significantly increased from $1,625 in Q3’24 to $302,506 in Q3’25.
• Generated Q3’25 Adjusted Revenue⁽³⁾ of $361,277.
• Realized gains – digital assets, Unrealized gains – digital assets, and Impairment loss – digital intangible assets were $6.9 million, $6.4 million, and $(6.3 million), respectively, combined totaling $7.1 million.
• Research and development expenses decreased 89% from $3.5 million in Q3’24 to $0.4 million in Q3’25.
• Selling, general and administrative expenses declined 30% from $3.7 million in Q3’24 to $2.6 million in Q3’25.
• Gain on extinguishment of liability and a reduction in accrued liability within other income was $2.2 million and $0.2 million respectively, combined totaling $2.4 million.
• Income from operations increased from a loss of $(7.3 million) in Q3’24 to income of $4.4 million in Q3’25, a record high for the Company.
• Net income increased from a loss of $(7.9 million) in Q3’24 to income of $6.6 million in Q3’25, a record high for the Company.
• Net income attributable to participating securities was $5.8 million in Q3’25.
• Net income per common share in Q3’25 from a basic and diluted perspective was $0.26 and $0.05, respectively.
• Adjusted EBITDA⁽³⁾ was $8.0 million in Q3’25.
  
  

Validator Operating Results

• In 2025, the Company launched a co-brand validator, “Kinetiq x Hyperion”. A definitive Joint Validator Agreement was executed in October 2025 among the Company, Kinetiq, and Pier Two.
• The number of HYPE tokens staked at the Kinetiq x Hyperion Validator was 8.2 million as of September 30, 2025 and 13.2 million as of October 31, 2025, a 60% month-over-month increase.⁽⁴⁾

Cash Flow

• Net cash used in operating activities decreased from $(24.0 million) for the nine months ended September 30, 2024 to $(10.7 million) for the nine months ended September 30, 2025.
• Net cash used in investing activities increased from $(0.2 million) for the nine months ended September 30, 2024 to $(65.6 million) for the nine months ended September 30, 2025, primarily as a result of the purchase of HYPE tokens pursuant to the Company’s digital asset treasury strategy, which launched in June 2025.

Balance Sheet and Liquidity

• Cash and cash equivalents totaled $8.2 million as of September 30, 2025.
• HYPE – digital assets totaled $38.0 million market value, and Gross HYPE Holdings⁽³⁾ totaled $77.8 million market value on 1.7 million tokens as of September 30, 2025.
• Debt totaled $7.7 million as of September 30, 2025 (net of debt discount of $0.6 million).
• Net asset value⁽³⁾ totaled $74.5 million as of September 30, 2025.

Financial Guidance

• We anticipate Q4’25 Adjusted Revenues of $475,000 to $515,000, representing 31% to 43% Quarter-on-Quarter Growth versus Q3’25.
• We anticipate our operating cash flow to turn positive in 2026.

(1) All financial information in this press release is unaudited. Throughout this document, totals may not sum due to rounding. Calculations are based on unrounded results. N.M. is the abbreviation for "Not Meaningful".

(2) “HYPE – Digital Assets”, a GAAP measure, does not include HiHYPE, which is Hyperion’s liquid staking HYPE token.

(3) See “Non-GAAP Financial Measures” below for an explanation and reconciliations of non-GAAP measures used throughout this press release.

(4) Supplemental operating disclosure; information on the number of tokens staked at the Company’s validator is available real-time via public sources.

(5) Unaudited supplemental disclosure more fully described on the Reconciliation of GAAP HYPE - Digital Assets to Non-GAAP Gross HYPE Holdings.

Description of Business Activities in Q3’25

Hyperion DeFi is the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid’s native token, HYPE. The Company is focused on providing its shareholders with simplified access to the Hyperliquid ecosystem, one of the fastest growing, highest revenue-generating blockchains in the world. Shareholders benefit from a gradually compounding exposure to HYPE, both from its native staking yield and additional revenues generated from its unique on-chain utility.

The Company’s Q3’25 operating business activities are summarized below:

1. Staking Rewards: The Company stakes its HYPE to its Validator and earns rewards.
2. Validator Commissions: The Company operates its Validator under a Joint Validator Operators Agreement (together with Kinetiq and Pier Two) and earns commissions on rewards delivered to third-party tokens delegated to the Validator.
3. Yield Enhancement: The Company pursues accretive strategies to enhance yield earned on its tokens.
   • In Q3’25, this included the launch of the Company’s “HiHYPE” (Hyperion iHYPE) liquid staking token, gains on covered call option strategies (included in the realized and unrealized gains on digital assets income statement line items), and certain liquid staking activities.
4. DeFi Monetization: The Company supports and monetizes DeFi activity on the Hyperliquid blockchain with sustainable, scalable practices.
   • In Q3’25, this included the launch of the Company’s proprietary “HAUS” platform (“HYPE Asset Use Service”), which allows its clients to unlock unique utility on Hyperliquid while generating fee income for Hyperion DeFi.
   • The Company announced its first HAUS transaction with Credo in September 2025, which enables Credo to receive the benefit of lower trading fees on the Hyperliquid decentralized exchange, with Hyperion DeFi receiving a portion of those savings as income (while continuing to earn staking rewards).
   • The Company’s second HAUS transaction was announced with Felix in October 2025, enabling Felix’s launch of new financial markets on the Hyperliquid blockchain, with Hyperion DeFi receiving a portion of fees generated from their markets (while continuing to earn staking rewards).
5. Ecosystem Rewards: Through its active participation in the Hyperliquid DeFi ecosystem, the Company positions itself for the receipt of future potential token airdrops, protocol incentives, and other rewards that may become available periodically. In Q3’25, the Company’s Validator received over 3 million tokens delegated from the Hyperliquid Foundation.
6. Life Sciences: Hyperion DeFi continues to develop its proprietary Optejet User Filled Device (UFD).

Conference Call & Webcast

Hyperion DeFi, Inc. will host a conference call to discuss third quarter 2025 results at 5:00 p.m. Eastern Time on November 13, 2025. A slide presentation that includes supplemental financial information and reconciliations of certain non-GAAP measures to their most directly comparable GAAP measures can be accessed through the Company’s Investor Relations website at along with information for the conference call. Participants may submit questions in advance of the call via email to . A webcast of the call will be archived and available through Thursday, November 27, 2025 at 11:59 on the Company's website.

Presentation

All growth rates represent year-over-year comparisons, except as otherwise noted. All amounts in tables are presented in U.S. dollars, rounded to the nearest dollar, except as otherwise noted. As a result, certain amounts and rates may not sum or recalculate using the rounded dollar amounts provided.

About the Hyperliquid Platform and the HYPE Token

Hyperliquid is a next-generation layer one blockchain optimized for high frequency, transparent trading. The blockchain includes fully on-chain perpetual futures and spot order books, with every order, cancel, trade, and liquidation occurring within 70 millisecond block times. It also hosts the HyperEVM, a general-purpose smart contract platform that supports permissionless decentralized financial applications akin to Ethereum.

HYPE is the native token of Hyperliquid. Staked HYPE provides utility for users via reduced trading fees and increased referral bonuses. As of October 2025, more than 30 million HYPE have been autonomously purchased and sequestered by the blockchain with the trading fees generated on the network’s central limit order books.

About Hyperion DeFi, Inc.

Hyperion DeFi, Inc. is the first U.S. publicly listed company building a long-term strategic treasury of HYPE. The Company provides investors with streamlined access to the Hyperliquid ecosystem, one of the fastest growing, highest revenue-generating blockchains in the world. Shareholders benefit from compounding exposure to HYPE, both from its native staking yield and additional revenues generated from its unique on-chain utility.

Hyperion DeFi is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers.

For more information, please visit Hyperiondefi.com.

Forward Looking Statements; Disclaimer

Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements, our future activities or other future events or conditions, including the estimated market opportunities for our platform technology, the viability of, and risks associated with, our cryptocurrency treasury strategy, and the growth and revenue potential of the Hyperliquid ecosystem and the growth prospects of the Company. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission (the “SEC”).

Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Hyperion DeFi does not undertake any obligation to update any forward-looking statements.

Certain information contained in this press release and statements made orally during the corresponding earnings call relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Hyperion DeFi’s own internal estimates and research. While Hyperion DeFi believes these third-party studies, publications, surveys and other data to be reliable as of the date of this press release, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of Hyperion DeFi’s internal estimates or research and no reliance should be made on any information or statements made in this press release relating to or based on such internal estimates and research. You should conduct your own investigation and analysis of Hyperion DeFi, its business, prospects, results of operations and financial condition. In furnishing this information, Hyperion DeFi does not undertake any obligation to provide you with access to any additional information (including forward-looking information and any projections contained herein) or to update or correct the information.

Hyperion DeFi, Inc. Investor Contact:

Jason Assad

Hyperion DeFi, Inc.



(678) 570-6791

_____________________

[1] Includes gross proceeds of $5,851,007 less total issuance costs of $187,741.

[2] Includes gross proceeds of $1,039,206 less total issuance costs of $116,456. Also note that incremental value and non-cash warrant modification and additional warrants issuance costs related to the warrant inducement entered into on January 16, 2025 offset to a zero balance.

[3] Includes gross proceeds of $50,000,000 less total issuance costs of $634,250.

[4] Includes gross proceeds of $2,657,659 less total issuance costs of $98,519.

[5] Includes gross proceeds of $22,489,548 less total issuance costs of $705,603.

[6] Partial exercise of the Armistice warrants.

_____________________

[7] Includes gross proceeds of $3,293,347 less total issuance costs of $98,800.

[8] Includes gross proceeds of $2,000,000 less total issuance costs of $111,171.

[9] Shares issued as partial consideration for License Agreement with Formosa Pharmaceuticals Inc.

[10] Shares issued in partial consideration for reacquisition of License Agreement with Bausch & Lomb Ireland Limited.

[11] Includes gross proceeds of $1,728,804 less total issuance costs of $51,868.

[12] Includes gross proceeds of $14,139,994 less total issuance costs of $1,791,816.

[13] Offering includes modification of warrants and additional warrants in the July 2024 offering.

[14] Non-cash warrant modification and additional warrants issuance costs related to one of the offerings of $2,868,000 are shown on a separate line item.

[15] Includes gross proceeds of $1,212,251 less total issuance costs of $36,368.

Non-GAAP Financial Measures

In addition to our results determined in accordance with GAAP, this press release and the accompanying tables contain Adjusted Revenue, Gross HYPE Holdings, Net Asset Value, and Adjusted EBITDA, which are non-GAAP financial measures. Adjusted Revenue, Gross HYPE Holdings, Net Asset Value, and Adjusted EBITDA are unaudited, presented as supplemental disclosure, and should not be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

It is important to note that the particular items we exclude from, or include in, Adjusted Revenue, Gross HYPE Holdings, Net Asset Value, and Adjusted EBITDA may differ from the items excluded from, or included in, similar non-GAAP financial measures used by other companies in the same industry. We also periodically review our non-GAAP financial measures and may revise these measures to reflect changes in our business or otherwise.

“Adjusted Revenue” reflects all staking, commissions, and gross operational, asset-generating business activity in-period. It is reconciled to the GAAP measure “Revenue” by adding accumulated but unrealized rewards on HiHYPE. Staking rewards are not recognized from a GAAP Revenue perspective on our liquid staking token; instead, conversion back from HiHYPE into HYPE may result in a gain in connection with recognizing the market value of HYPE (including earned staking rewards) versus derecognizing the carrying value of HiHYPE upon conversion. We believe Adjusted Revenue provides a more complete view of our staking activities and overall recurring business profile, without potential period-to-period variability due to HiHYPE liquid staking activities. As such, Adjusted Revenue is an important metric used by our management for financial, risk management and operational decision-making, and provides an additional tool for investors to use to understand and compare our operating results across accounting periods.

“Gross HYPE Holdings” is the gross market value of the Company’s HYPE assuming all HiHYPE tokens were converted back to HYPE tokens as of September 30, 2025. It is reconciled to the GAAP measure “HYPE - Digital Assets” by adding (i) HiHYPE Tokens at carrying value and (ii) the unrealized accretion (dilution) expected upon HiHYPE to HYPE reconversion as of September 30, 2025. We believe Gross HYPE Holdings is a helpful non-GAAP financial measure to our management and investors because it eliminates the temporary financial impacts caused by the conversion of HYPE tokens into HiHYPE tokens, which (a) derecognizes staking rewards and commissions on our HiHYPE tokens and (b) does not recognize upward mark-to-market movements in underlying HYPE tokens given HiHYPE is carried at the lower of cost basis or impaired value. As such, it provides useful information about our balance sheet, allows for greater transparency with respect to important metrics used by our management for financial, risk management and operational decision-making, and provides an additional tool for investors to use to understand and compare our operating results across accounting periods.

“Net Asset Value” is the market value of our marketable digital assets less net outstanding debt. It is reconciled to the GAAP measure “HYPE - Digital Assets” by (i) adding HiHYPE Tokens at carrying value, (ii) adding the unrealized accretion (dilution) expected upon HiHYPE to HYPE reconversion, (iii) adding Current Assets, (iv) subtracting Current Liabilities, and (v) subtracting Notes Payable (Non-current portion, without subtracting corresponding debt discounts or any unamortized issuance expenses). We believe Net Asset Value is a helpful non-GAAP financial measure to our management and investors because it provides a more complete picture of our net liquid and marketable assets. It does not include Other Digital Assets which may not be immediately marketable. It does not include other non-current assets or non-current liabilities beyond the aforementioned items. The Company believes Net Asset Value provides useful information about our balance sheet and financial performance, enhances the overall understanding of our past performance and future prospects, allows for greater transparency with respect to important metrics used by our management for financial, risk management and operational decision-making, and provides an additional tool for investors to use to understand and compare our operating results across accounting periods.

“Adjusted EBITDA” is a financial earnings measure meant to reflect management’s view of recurring business activities and a more comparable view of the mark-to-market impacts on our digital asset treasury holdings in-period. It is reconciled to the GAAP measure “Net Income (Loss)” by removing (i) equity based compensation, (ii) interest expense, (iii) income taxes, (iv) depreciation and amortization expense (excluding amortization of operating lease), (v) non-recurring gains from reductions in life sciences liabilities, and (vi) other non-recurring items which we do not consider material in nature; and, it adds the in-period change in unrealized accretion (dilution) expected upon HiHYPE to HYPE reconversion. The items excluded from our Adjusted EBITDA are excluded because they are non-cash in nature, or because the amount and timing of these items are unpredictable, are not driven by core results of operations, and render comparisons with prior periods and competitors less meaningful. We add to Adjusted EBITDA the in-period change in unrealized accretion (dilution) expected upon HiHYPE to HYPE reconversion to give a more complete picture of mark-to-market impacts on our HYPE holdings, disregarding the temporary conversion of HYPE to HiHYPE. Adjusted EBITDA is used by management, in addition to GAAP financial measures, to understand and compare our operating results across accounting periods, for risk management and operational decision-making purposes. This non-GAAP measure provides investors with additional information in evaluating the Company's operating performance.

Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool.

(5) Represents staking rewards on staked HYPE tokens which have been derecognized and converted into HiHYPE, which is Hyperion DeFi’s liquid staking token. Staking rewards are not recognized from a GAAP Revenue perspective on our liquid staking token; instead, conversion back from HiHYPE into HYPE may result in a gain in connection with recognizing the market value of HYPE (including earned staking rewards) versus derecognizing the carrying value of HiHYPE upon conversion.

(6) Represents the estimated future financial implications if all company-owned HiHYPE tokens were reconverted to HYPE as of September 30, 2025. Encapsulates both the conversion of HiHYPE to HYPE plus the realization of previously accrued but unrecognized staking rewards.

(7) Represents the change in “Unrealized accretion (dilution) upon future HiHYPE to HYPE reconversion” versus June 30, 2025. The Company did not hold any HiHYPE tokens on or prior to June 30, 2025.

(8) Unaudited supplemental disclosure.

(9) Non-current portion; does not subtract debt discount of $598,691 as of September 30, 2025.

(10) Does not include Amortization of Operating Lease.

(11) Gain on extinguishment of liability and a reduction in accrued liability within other income was $2.2 million and $0.2 million respectively, combined totaling $2.4 million.

(12) Includes gains on sales of equipment, release of reserves held against potential returns of company-sold items, and a one-time realized payment in connection with a terminated LOI.